🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Treatment-free remission (TFR) in Ph+ ALL. 🧵 on our recent paper (link below) 👉 Unlike CML, no TFR concept exists in Ph+ ALL. This is more relevant nowadays when increasing numbers of pts are not allo-transplanted in CR1 for Ph+ ALL. Question in clinic- how long should I

ICYMI: Dr. Kantarjian on 40 years of progress in CML care Hagop Kantarjian,MD MD Anderson Cancer Center Watch the video: sohoinsider.com/roundtable-dis…

Oral formulation of arsenic trioxide has similar pharmacokinetics to the intravenous drug, allowing potential future all oral therapy in acute promyelocytic leukemia MD Anderson Cancer Center #Leukemia doi.org/10.1182/blooda… ASH #leusm

Expert recommendations on using MRD in #ALL now out in Blood Advances. ClonoSEQ (NGS MRD) is superior to other MRD methods and should guide decisions about CAR T-cells or SCT MD Anderson Cancer Center #Leukemia doi.org/10.1182/blooda… #leusm

New research from MD Anderson Cancer Center investigators presents outcomes in FLT3-mutated acute myeloid leukemia acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… Alex Bataller Tapan Kadia Naval Daver, M.D. Nicholas Short MD Musa Yilmaz, MD Gautam Borthakur Ghayas Issa Hagop Kantarjian,MD OncoAlert #LeuSM #AML

In this large retrospective study of FLT3-mutated AML, we confirm the important role of FLT3 inhibitors in intensively treated pts and demonstrate promising outcomes w/ low-intensity triplets in older/unfit pts. MD Anderson Cancer Center #Leukemia ACS Journal Cancer doi.org/10.1002/cncr.3…

🙂 Very Happy to share this comprehensive review on AML, from an MD Anderson Cancer Center perspective, discussing all that is new and exciting in the field 🩸 Hagop Kantarjian,MD ➡️ Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges ACS

Check out our comprehensive review of Chronic Myeloid Leukemia published in JAMA Listen to our interview available through the link: jamanetwork.com/journals/jama/… MD Anderson Cancer Center #Leukemia @ EJabbour Hagop Kantarjian,MD #leusm #CML

Check out our comprehensive review on #AML from an MD Anderson Cancer Center perspective, " Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges" published in ACS Journal Cancer acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… #leusm

New article led by Hagop Kantarjian,MD provides a comprehensive overview of olverembatinib for treating chronic myeloid leukemia, including historical development, current status, and future research: acsjournals.onlinelibrary.wiley.com/doi/full/10.10… OncoAlert Fadi Haddad, MD #LeuSM #CML

Ph 1b/2 trial of Aza-Ven-Magro in newly-diagnosed high-risk and R/R #AML: Clinical data & correlative analysis, published in Clinical Cancer Research doi.org/10.1158/1078-0… Unfortunately, the neg Ph3 ENHANCE trials terminates research w/ Magrolimab and likely anti-CD47 Rx in AML for now

First report of the Ph 2 trial of the CLIA regimen in pts w/ R/R #AML: CR/CRi of 49% & median OS of 12 months in pts who received it as 1st salvage rx. Data provides tolerable & effective backbone upon which to build combination strategies ACS Journal Cancer doi.org/10.1002/cncr.3…

Historical development, current status, and future research of olverembatinib, a new third-generation BCR::ABL1 TKI with significant activity and favorable safety profile: MD Anderson Cancer Center #Leukemia Fadi Haddad, MD dx.doi.org/10.1002/cncr.3… #leusm #CML

👉👉👉Our group’s new article led by Dr Hannah Goulart & Dr Tapan Kadia Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia AML acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… | ACS Journal Cancer MD Anderson Cancer Center #leusm #endcancer | Sanam Loghavi, MD صنم لغوی 🔬🧬

👉👉👉Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase 1b/2 Study and Correlative Analysis | Led by .Naval Daver, M.D. & Hussein Abbas aacrjournals.org/clincancerres/… | MD Anderson Cancer Center #leusm #endcancer Clinical Cancer Research Cancer Discovery

This new review article led by Hagop Kantarjian,MD & colleagues details the ongoing revolutionary paradigm shift in acute lymphoblastic leukemia (ALL) treatment, focusing on adult ALL and breakthrough targeted treatments: acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… OncoAlert #LeuSM

New in Leukemia Journal : Outcomes in intensively treated KMT2Ar #AML have improved over time. But low-intensity therapies still show poor results — highlighting the urgent need to explore menin inhibitors nature.com/articles/s4137… #leusm

WBC >70K (but not IKZF1plus) increases risk of relapse with blina+ponatinib in Ph+ ALL, particularly extramedullary/CNS. Pts with high WBC should be considered for systemic MTX/Ara-C and/or CAR T-cell consolidation jhoonline.biomedcentral.com/articles/10.11… #leusm #ALL

The past decade has witnessed remarkable advances in deciphering the pathophysiology of acute lymphoblastic leukemia (ALL) and in developing novel targeted therapies. Revisit this comprehensive review by Hagop Kantarjian,MD et al: acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… OncoAlert #LeuSM

👉👉👉Just out in AmericanJournalofHematology - our group’s new paper led by .Tapan Kadia & Hagop Kantarjian,MD || Ph2 study Results CPX-351+VEN for patients w/ R/R AML (n=33;44%2nd Salvage Tx or later;30%prior SCT:: ORR=46% w/CRc 39%) #leusm #endcancer | onlinelibrary.wiley.com/doi/10.1002/aj… | Sanam Loghavi, MD صنم لغوی 🔬🧬